News on Mendelian diseases, hereditary cancer, variant classification, cystic fibrosis testing and more.
The companies will offer free testing to more rapidly identify individuals with certain mutations, supporting Inozyme's efforts to develop and test new treatments.
Rainbow will offer Color's hereditary cancer and heart health genetic risk assessment tests to patients in Hong Kong.
Researchers from the molecular diagnostics firm said their screen could identify a range of variant types to boost the identification of at-risk couples.
Seventy-eight percent of participants had at least one positive carrier screening result and 3.5 percent had a medically actionable secondary finding.
The Australian Genomics Health Futures Mission will include a series of studies to tackle rare diseases and cancers.
